Andrew L. Feldman, Surendra Dasari, Lisa M. Rimsza, David W. Scott, Naoki Oishi, Guangzhen Hu, Pedro Farinha, Catalina Amador, Elı́as Campo, Wing C. Chan, James R. Cook, Jan Delabie, Kai Fu, Timothy C. Greiner, Laura K. Hilton, Giorgio Inghirami, Javeed Iqbal, Elaine S. Jaffe, Ryan D. Morin, Sarah L. Ondrejka, G. Ott, Stefania Pittaluga, Philipp W. Raess, Andreas Rosenwald, Kerry J. Savage, Graham W. Slack, Susan L. Slager, Joo Y. Song, George Wright, Hao‐Wei Wang, Yu Zeng, Tadashi Yoshino, Xiaojun Wu, Ryan A. Wilcox, Xueju Wang, Min Shi, Akira Satou, Anamarija M. Perry, Roberto N. Miranda, L. Jeffrey Medeiros, Matthew J. Maurer, Eric Mou, Young Hyeh Ko, Kennosuke Karube, Brad S. Kahl, Liuyan Jiang, David L. Jaye, Alejandro A. Gru, Laurence de Leval, Weina Chen, Jennifer R. Chapman, James R. Cerhan, Carlos Barrionuevo, Stephen M. Ansell, Ahmed A. Aljudi
ABSTRACT: Anaplastic large cell lymphomas (ALCLs) are CD30+ T-cell lymphomas that share pathologic features but differ in presentation, outcome, and genetics. Current classification incorporates clinical presentation and anaplastic lymphoma kinase (ALK) status but inadequately addresses molecular heterogeneity and therapeutic vulnerabilities. We studied 689 patients with ALCL in the LLMPP (Lymphoma/Leukemia Molecular Profiling Project) and performed expert consensus review, genetic subtyping (ALK, DUSP22, TP63, and triple negative), and immunohistochemistry for phosphorylated STAT3Tyr705. RNA sequencing with unsupervised gene expression profiling in 393 patients identified 2 main molecular types of ALCL that could be predicted with 91% accuracy based on the presence (type I) or absence (type II) of phosphorylated STAT3Y705 expression. Type I ALCLs included ALK+ ALCL and a subset of triple-negative ALCLs (TN-I); type II ALCLs included tumors with DUSP22 and/or TP63 rearrangements and the remaining triple-negative ALCLs (TN-II). Type I ALCLs were enriched for JAK-STAT3, whereas type II ALCLs were enriched for non-tyrosine kinase pathways, particularly epigenetic regulators such as EZH2. Immunohistochemistry showed overexpression of EZH2 and its trimethylated substrate H3K27. Prognosis in systemic ALCL was favorable for DUSP22-rearranged ALCL (5-year overall survival, 95%) and ALK+ ALCL (88%), intermediate for triple-negative ALCL (TN-I, 52% and TN-II, 37%), and poor for TP63-rearranged ALCL (0%). We introduce an integrated molecular classification that preserves currently diagnosed ALCL entities but identifies 4 molecularly distinct ALK- ALCL subtypes (DUSP22-rearranged, TP63-rearranged, TN-I, and TN-II). This classification can be easily implemented on paraffin tissue in routine practice or clinical trials, and stratifies ALCL into diagnostically, prognostically, biologically, and potentially therapeutically relevant subtypes.